Clearmind Medicine (CMND) Stock Price, News & Analysis

Company Overview

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key Stats

• Today's Range: $0.97 to $1.03
• 50-Day Range: $0.84 to $1.16
• 52-Week Range: $0.80 to $2.18
• Volume: 55,141 shs
• Average Volume: 69,827 shs
• Market Capitalization: $4.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CMND Stock Analysis - Frequently Asked Questions

How have CMND shares performed this year?

Clearmind Medicine's stock was trading at $1.38 at the beginning of the year. Since then, CMND stock has decreased by 25.4% and is now trading at $1.03.

How were Clearmind Medicine's earnings last quarter?

Clearmind Medicine Inc. (NASDAQ:CMND) released its quarterly earnings data on Thursday, June, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter.

When did Clearmind Medicine's stock split?

Shares of Clearmind Medicine reverse split on Tuesday, November 28th 2023.The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Clearmind Medicine IPO?

Clearmind Medicine (CMND) raised $9 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 1,300,000 shares at a price of $6.00-$8.00 per share. Aegis Capital Corp. acted as the underwriter for the IPO.

Who are Clearmind Medicine's major shareholders?

Top institutional investors of Clearmind Medicine include AdvisorShares Investments LLC (4.82%).

How do I buy shares of Clearmind Medicine?

Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Clearmind Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clearmind Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), AppLovin (APP) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 6/12/2025
• Today: 8/23/2025
• Next Earnings (Estimated): 9/15/2025
• Fiscal Year End: 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMND
• CIK: 1892500
• Web: www.clearmindmedicine.com
• Phone: 604-260-1566
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -164.79%
• Return on Assets: -71.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.74
• Quick Ratio: 1.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.73 per share
• Price / Book: 1.41

Miscellaneous

• Outstanding Shares: 4,265,000
• Free Float: N/A
• Market Cap: $4.39 million
• Optionable: Not Optionable
• Beta: 0.96